ArticleFrontiers in immunology2026
The neoantigen and associated tumour microenvironment in long-term survivors with oesophageal adenocarcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oesophageal adenocarcinoma (OAC) is a highly mutated cancer with poor survival. While outcomes are improving, long-term survival remains elusive for the majority of patients. Immunotherapy in combination with chemotherapy has shown benefit but is effective in only a subset of patients, highlighting the lack of reliable genomic biomarkers for response and survival. Effective anti-tumour immune responses, including those targeting neoantigens, are critical for durable outcomes. However, their role in long-term OAC survivors remains poorly understood. Methods: Whole-genome, whole-exome, and RNA sequencing data was used to identify (expressed) putative neoantigens from two independent OAC cohorts. We combined data from the Extended-DOCTOR (ExtDOC; n=149) and the TCGA ESCA (n=88) cohort to profile the neoantigen landscape in OAC. 95 patients of the ExtDOC cohort were enrolled in the DOCTOR trial, sponsored by the GI Cancer Trials. Selected putative neoantigens from 14 patients underwent Results: We identified a median of 23 neoantigens per tumour sample which were mostly 9- and 10-mers predicted to bind to HLA-A molecules. Low stromal and immune exclusion scores as well as high-quality neoantigens with high expressed differential agretopicity index (DAI), a measure of immunogenicity, were linked to good survival outcomes. We observed intra-tumour heterogeneity and found immunogenic putative neoantigens for 12/14 patients. The tumour environment (TME) revealed three immune clusters which were associated with patient outcomes. Conclusions: We showed that OAC is characterised by a complex and largely immunosuppressive TME. In our cohort, patients with an immune-enriched TME had more favourable outcomes, including higher response rates, lower disease recurrence and longer survival. This might be linked to the presence of high-quality neoantigens. Together, these findings provide a rationale for the development of tailored, immune-informed treatment strategies in OAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.